KR102354902B1 - 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도 - Google Patents

폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도 Download PDF

Info

Publication number
KR102354902B1
KR102354902B1 KR1020157035048A KR20157035048A KR102354902B1 KR 102354902 B1 KR102354902 B1 KR 102354902B1 KR 1020157035048 A KR1020157035048 A KR 1020157035048A KR 20157035048 A KR20157035048 A KR 20157035048A KR 102354902 B1 KR102354902 B1 KR 102354902B1
Authority
KR
South Korea
Prior art keywords
delete delete
group
alkyl
compound
polymyxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157035048A
Other languages
English (en)
Korean (ko)
Other versions
KR20160009041A (ko
Inventor
파멜라 브라운
마이클 도슨
모나 시모노빅
스티븐 보악스
에스더 두페르치
Original Assignee
에버레스트 메디신즈 (싱가포르) 피티이. 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201309248A external-priority patent/GB201309248D0/en
Priority claimed from GB201404301A external-priority patent/GB201404301D0/en
Application filed by 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 filed Critical 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드
Publication of KR20160009041A publication Critical patent/KR20160009041A/ko
Application granted granted Critical
Publication of KR102354902B1 publication Critical patent/KR102354902B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020157035048A 2013-05-22 2014-05-21 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도 Active KR102354902B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201309248A GB201309248D0 (en) 2013-05-22 2013-05-22 Compounds and combinations
GB1309248.1 2013-05-22
GB201404301A GB201404301D0 (en) 2014-03-11 2014-03-11 Compounds and combinations
GB1404301.2 2014-03-11
PCT/GB2014/051547 WO2014188178A1 (en) 2013-05-22 2014-05-21 Polymyxin derivatives and their use in combination therapy together with different antibiotics

Publications (2)

Publication Number Publication Date
KR20160009041A KR20160009041A (ko) 2016-01-25
KR102354902B1 true KR102354902B1 (ko) 2022-01-24

Family

ID=50829204

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157035048A Active KR102354902B1 (ko) 2013-05-22 2014-05-21 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도

Country Status (20)

Country Link
US (1) US10407467B2 (enExample)
EP (1) EP2999711B1 (enExample)
JP (1) JP6643758B2 (enExample)
KR (1) KR102354902B1 (enExample)
CN (1) CN105308065B (enExample)
BR (1) BR112015029309A2 (enExample)
CA (1) CA2939061C (enExample)
CY (1) CY1125479T1 (enExample)
DK (1) DK2999711T3 (enExample)
ES (1) ES2923762T3 (enExample)
HR (1) HRP20220898T1 (enExample)
HU (1) HUE059544T2 (enExample)
LT (1) LT2999711T (enExample)
PL (1) PL2999711T3 (enExample)
PT (1) PT2999711T (enExample)
RS (1) RS63484B1 (enExample)
RU (1) RU2730012C2 (enExample)
SI (1) SI2999711T1 (enExample)
TW (1) TWI665218B (enExample)
WO (1) WO2014188178A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX355217B (es) 2011-11-18 2018-04-10 New Pharma Licence Holdings Ltd Derivados de polimixina.
HUE059544T2 (hu) 2013-05-22 2022-11-28 Spero Therapeutics Inc Polimixin-származékok és ezek alkalmazása kombinációs terápiában különbözõ antibiotikumokkal
EP3038615A4 (en) * 2013-08-28 2017-04-12 The Medicines Company Methods for treating bacterial infections using oritavancin and polymyxins
KR20160135739A (ko) * 2014-03-11 2016-11-28 뉴 파마 라이센스 홀딩스 리미티드 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도
CN107108699A (zh) 2014-11-26 2017-08-29 新药物许可控股有限公司 化合物
EP3233889B1 (en) * 2014-12-16 2022-07-06 Shanghai MicuRx Pharmaceutical Co., Ltd. Antimicrobial polymyxins for treatment of bacterial infections
FI126143B (en) 2015-01-15 2016-07-15 Northern Antibiotics Oy Polymyxine derivative and its uses
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
KR101790296B1 (ko) * 2015-03-26 2017-10-26 한국생명공학연구원 네트롭신을 유효성분으로 포함하는 그람음성 세균에 대한 폴리믹신의 항균 활성을 증가시키는 조성물
WO2016166103A1 (en) * 2015-04-13 2016-10-20 Xellia Pharmaceuticals Aps Polymyxin derivatives
JP7367950B2 (ja) * 2015-09-29 2023-10-24 モナッシュ ユニバーシティ 抗菌性ポリミキシン誘導体化合物
CN109789125B (zh) * 2016-08-16 2022-10-18 罗切斯特大学 含有基于多粘菌素b/甲氧苄啶的治疗剂的药物组合物
CN106631902A (zh) * 2016-09-23 2017-05-10 上海步越化工科技有限公司 一种特拉万星侧链癸基(2‑氧代乙基)氨基甲酸9h‑芴‑9‑甲基酯的制备方法
US11191773B2 (en) 2017-07-17 2021-12-07 President And Fellows Of Harvard College Methods of treatment for bacterial infections
CN111247162B (zh) * 2017-10-31 2022-02-18 正大天晴药业集团股份有限公司 多黏菌素类似物及其制备方法
WO2019084628A1 (en) 2017-11-02 2019-05-09 The University Of Queensland Peptide antibiotics
US11713335B2 (en) 2018-03-12 2023-08-01 President And Fellows Of Harvard College Aminocoumarin compounds and methods of their use
DK3810633T3 (da) 2018-06-25 2024-01-15 Spero Therapeutics Inc Forbindelser
CN111690040A (zh) * 2019-03-12 2020-09-22 上海来益生物药物研究开发中心有限责任公司 多粘菌素衍生物、其制备方法和应用
CN110179967A (zh) * 2019-05-28 2019-08-30 中国医药集团总公司四川抗菌素工业研究所 多粘菌素母核和一种抗生素的组合物及其应用
WO2021150792A1 (en) 2020-01-21 2021-07-29 Micurx Pharmaceuticals, Inc. Novel compounds and composition for targeted therapy of kidney-associated cancers
US20220395555A1 (en) * 2020-06-11 2022-12-15 Boris Farber Derivatives of antibiotics
US12472195B2 (en) 2020-07-02 2025-11-18 Purdue Research Foundation Inhalation formulations of antimicrobial compounds
TW202233649A (zh) 2020-11-06 2022-09-01 美商斯佩羅治療學股份有限公司 化合物
CN116847735B (zh) * 2021-02-02 2026-02-03 韩国生命工学研究院 含有联苯基衍生物化合物作为有效成分的抗菌佐剂及其用途
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds
WO2024003042A1 (en) 2022-06-28 2024-01-04 Breakthrough Biotech Drift Aps Novel combinations of sesquiterpene alcohols, polymyxins and nisin compounds as antimicobial and/or antifungal compounds
AU2023303408A1 (en) 2022-07-06 2024-12-19 Aligos Therapeutics, Inc. Anti-viral compounds
EP4611762A1 (en) * 2022-11-14 2025-09-10 Cipla Limited Novel ophthalmic composition
KR102952821B1 (ko) * 2022-11-23 2026-04-16 웰펩 주식회사 폴리믹신 e 및 폴리믹신 b의 제조방법
CN116212004A (zh) * 2022-12-07 2023-06-06 东南大学 一种复合抗生素吸入用粉剂及其制备方法与应用
IL326320A (en) * 2023-08-03 2026-04-01 Arcum Vision Inc Enhanced formulation of polymyxin b/ trimethoprim and rifampin and methods for ophthalmic uses
KR20250037611A (ko) * 2023-09-07 2025-03-18 웰펩 주식회사 그람 음성균 및 다제내성 그람 음성균에 우수한 항균 활성을 갖는 신규 폴리믹신 유사체, 이를 포함하는 항균용 조성물
WO2025236916A1 (en) * 2024-05-16 2025-11-20 Brii Biosciences, Inc. Compositions and methods for treating infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012168820A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
AU7753787A (en) 1986-08-06 1988-02-24 Jean-Luc Fauchere Production of covalent-linked conjugates from an antibiotic and a non-toxic derivative of polymyxine b
US20010021697A1 (en) 1987-09-14 2001-09-13 Henning Lowenstein Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
TW274552B (enExample) 1992-05-26 1996-04-21 Hoechst Ag
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
JP4583559B2 (ja) * 2000-07-24 2010-11-17 栄研化学株式会社 Ｍｒｓａスクリーニング用培地
JP2007507512A (ja) 2003-09-30 2007-03-29 コーヒ コーポレーション 熱傷を治療するための組成物および方法
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
WO2008001773A1 (fr) 2006-06-27 2008-01-03 Toyo Tire & Rubber Co., Ltd. pneu apte à rouler dégonflé
BRPI0715095B8 (pt) * 2006-08-11 2021-05-25 Northern Antibiotics Oy derivado de polimixina da fórmula geral (i); produto de combinação; composição farmacêutica; método para se sensibilizar bactérias gram-negativas a um agente antibacteriano; método para o desenvolvimento de antibióticos; método para a redução da toxicidade de polimixinas, octapeptinas naturais e seus derivados durante a aplicação das mesmas no tratamento de infecções em um indivíduo; método para melhorar as propriedades farmacocinéticas, de polimixinas, octapeptinas naturais e seus derivados; método para a sensibilização de bactérias gram-negativas clinicamente importantes a um complemento de mecanismo de defesa presente no soro; uso de um derivado; e processo para a preparação de um derivado de polimixina da fórmula (i).
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
FI20085469A0 (fi) * 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
ES2334547B1 (es) 2008-09-10 2010-12-03 Universidad De Barcelona Compuestos peptidicos antibacterianos.
WO2010075416A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
JP5493387B2 (ja) * 2009-02-25 2014-05-14 国立大学法人 東京大学 選択培地の製造方法及びその利用
CN101851270A (zh) 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
WO2010130007A1 (en) 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (en) 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
US9226786B2 (en) * 2011-03-22 2016-01-05 Lexion Medical Llc Medical devices for clearing a surgical site
MX355217B (es) * 2011-11-18 2018-04-10 New Pharma Licence Holdings Ltd Derivados de polimixina.
HUE059544T2 (hu) 2013-05-22 2022-11-28 Spero Therapeutics Inc Polimixin-származékok és ezek alkalmazása kombinációs terápiában különbözõ antibiotikumokkal
US10047126B2 (en) 2014-04-01 2018-08-14 Monash University Polymyxin derivatives as antimicrobial compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012168820A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Antimicrobial Agents Chemotherapy, Vol.54, No.8, p.3341-3346(2010)
J. Peptide Res., Vol. 57, p.175-187(2001)
Microbial Drug Resistance, Vol.18, No.2, p.132-136(2012)
Peptide Sci., Vol. 45, p.243-244(2008)

Also Published As

Publication number Publication date
HUE059544T2 (hu) 2022-11-28
PT2999711T (pt) 2022-07-29
PL2999711T3 (pl) 2022-09-26
US10407467B2 (en) 2019-09-10
CA2939061A1 (en) 2014-11-27
CN105308065B (zh) 2021-10-15
CA2939061C (en) 2023-10-24
KR20160009041A (ko) 2016-01-25
SI2999711T1 (sl) 2022-10-28
HK1221474A1 (en) 2017-06-02
DK2999711T3 (da) 2022-07-18
EP2999711B1 (en) 2022-06-29
TW201444876A (zh) 2014-12-01
HRP20220898T1 (hr) 2022-10-14
WO2014188178A9 (en) 2015-01-08
JP2016527186A (ja) 2016-09-08
RU2015148032A (ru) 2017-06-27
JP6643758B2 (ja) 2020-02-12
EP2999711A1 (en) 2016-03-30
CN105308065A (zh) 2016-02-03
US20160222061A1 (en) 2016-08-04
TWI665218B (zh) 2019-07-11
CY1125479T1 (el) 2026-02-25
LT2999711T (lt) 2022-09-12
RS63484B1 (sr) 2022-09-30
RU2730012C2 (ru) 2020-08-14
ES2923762T3 (es) 2022-09-30
WO2014188178A1 (en) 2014-11-27
BR112015029309A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
CN105308065B (zh) 多粘菌素衍生物及其在与不同抗生素的组合疗法中的用途
AU2012338571B2 (en) Polymyxin derivatives
EP3116897B1 (en) Polymyxin derivatives and their use in combination therapy together with different antibiotics
US20230340026A1 (en) Compounds
RS65128B1 (sr) Jedinjenja
AU2007237431A1 (en) Lysobactin amides
HK1221474B (en) Polymyxin derivatives and their use in combination therapy together with different antibiotics
HK1240940B (en) Polymyxin derivatives and their use in combination therapy together with different antibiotics

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5